Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist that regulates blood sugar through glucose-dependent mechanisms
1 Its also been shown to reverse paralysis induced by agents like succinylcholine, a drug specifically used to temporarily paralyze skeletal muscle during anesthesia
October 2024: FDA declared the tirzepatide shortage resolved
Here are some simple strategies to help you handle social situations with confidence and maintain balance: Stay Hydrated: Sip water consistently throughout the day to stay hydrated, especially if youre celebrating with festive beverages
The results demonstrated that the 25mg daily pill delivered clinically meaningful weight loss: Average weight loss of 13.6-16.6% compared to 2.2-2.7% with placebo 76% of participants achieved at least 5% weight loss versus 31% on placebo Over 30% achieved 20% or greater weight loss Significant improvements in blood pressure, cholesterol, and inflammatory markers These results are comparable to what weve seen with injectable Wegovy, which typically produces 12-15% weight loss
The relationship between GLP-1 receptor agonists and vision problems centres primarily on diabetic retinopathy , a complication of diabetes affecting the blood vessels in the retina